TQH 3906
Alternative Names: TQH-3906Latest Information Update: 07 Jan 2025
Price :
$50 *
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antipsoriatics
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Plaque psoriasis
Most Recent Events
- 01 Jan 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial for Inflammatory bowel diseases in China (PO, Capsule) (NCT06754891)
- 27 Aug 2024 Phase-II clinical trials in Plaque psoriasis in China (PO) (NCT06542614)
- 12 Aug 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Plaque Psoriasis in China (PO) (NCT06542614)